-
Nov 21, 2024 | 
hcplive.com | Ahmad Masri |Patrick Campbell
New data from the FOREST-HCM trial suggests use of aficamten could help patients with obstructive hypertrophic cardiomyopathy (oHCM) avoid needing to undergoing septal reduction therapy (SRT). Presented at American Heart Association (AHA) Annual Scientific Sessions 2024, data from a subgroup analysis of the trial suggested nearly 70% of SRT-eligible patients included in the trial were no longer eligible after 24 weeks of treatment with aficamten.
-
Nov 21, 2024 | 
hcplive.com | Ahmad Masri |Patrick Campbell
New research is shedding light on the evolving risk profile and baseline characteristics among patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the US.
-
Sep 26, 2024 | 
healio.com | Scott Buzby |Richard Smith |Ahmad Masri
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Aficamten was linked to improved exercise capacity and quality of life for patients with obstructive HCM. The benefit was likely due to cardiac remodeling and replacement fibrosis observed on cardiac MRI.
-
Sep 4, 2024 | 
jamanetwork.com | Ahmad Masri |Michael E. Nassif |Kansas City |Roberto Barriales-Villa
Key PointsQuestion
Does aficamten treatment improve exercise response beyond peak oxygen uptake (pVO2) measured by cardiopulmonary exercise testing in obstructive hypertrophic cardiomyopathy (HCM)? Findings
In the Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) randomized clinical trial, 282 patients with symptomatic obstructive HCM received aficamten or placebo for 24 weeks.
-
May 14, 2024 | 
cfrjournal.com | Harold Bays |Michael S. Kiernan |Finn Gustafsson |Ahmad Masri
HFA 2024 — Investigator, Prof Nicolas Girerd (University Hospital of Nancy, FR) joins us to discuss the findings from the TELESAT study (NCT06312501). This multicenter observational longitudinal cohort study investigated whether a Remote Patient Monitoring (RPM) program (Satelia®Cardio, Satelia) is able to prevent cardiac decompensation by detecting weak signals of decompensation early in patients with chronic heart failure in France.
-
Mar 5, 2024 | 
acpjournals.org | Ahmad Masri
Authors: Ahmad Masri, MD, MS; Harriette G.C. Van Spall, MD, MPHAffiliations: Oregon Health & Science University, Portland, Oregon, USA (A.M.)McMaster University, Hamilton, Ontario, Canada (H.G.V.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J24-0004. This article was published at Annals.org on 5 March 2024. ACP Journal Club is editorially independent from Annals of Internal Medicine.
-
Feb 2, 2024 | 
onlinelibrary.wiley.com | Ahmad Masri |Roberto Barriales-Villa |Perry M. Elliott
Introduction Non-obstructive hypertrophic cardiomyopathy (nHCM) is a growing segment of the population with hypertrophic cardiomyopathy (HCM); however, no evidence-based medical therapies have been shown to improve symptoms, quality of life, or exercise capacity.1 Aficamten is a next-in-class cardiac myosin inhibitor that targets hypercontractility and impaired myocardial relaxation.2 Aficamten appears to be safe and effective in patients with obstructive HCM (oHCM) studied in the phase 2...
-
Nov 4, 2023 | 
cgtlive.com | Ahmad Masri
This is the second part of an interview with Ahmad Masri, MD, MS. For the first part, click here. “The whole concept is that if you're able to identify an antigen on the plasma cells, then you are able to use a cell therapy approach in order to deplete and decrease those plasma cells.
-
Oct 26, 2023 | 
cgtlive.com | Ahmad Masri
October 26, 2023In observance of World Amyloidosis Day, the cardiologist at the Center for Hypertrophic Cardiomyopathy at Oregon Health & Science University discussed the changing landscape of care in this field. “I encourage everyone to continue to learn about amyloidosis: systemic amyloidosis, ATTR amyloidosis, light chain amyloidosis, as well as other types of amyloidosis. These are not ultra-rare diseases like people used to think. These are patients in our clinics not infrequently.
-
May 12, 2023 | 
pubmed.ncbi.nlm.nih.gov | Ahmad Masri |Nosheen Reza
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
